

U.S. Patent Appl. No. 09/762594
Attorney Docket No.: 076934-0277848

CLAIM AMENDMENTS

1-9. (Canceled)

10. (Allowed) A vector comprising the nucleic acid of claim 41.

11. (Allowed) The vector of claim 10, wherein said vector is an expression vector.

12. (Allowed) The vector of claim 10 that is a prokaryotic vector.

13. (Allowed) The vector of claim 10 that is a eukaryotic vector.

14. (Allowed) A host cell comprising the vector of claim 10.

15. (Allowed) A host cell of claim 14 that is a prokaryotic cell.

16. (Allowed) A host cell of claim 14 that is a eukaryotic cell.

17-40. (Canceled)

U.S. Patent Appl. No. 09/762594
Attorney Docket No.: 076934-0277848

41. (Allowed) An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence as set forth in SEQ ID NO: 2;
- (b) a nucleotide sequence encoding the polypeptide as set forth in SEQ ID NO: 7;
- (c) a nucleotide sequence complementary to (a) or (b).

42. (Cancel)

43. (Currently Amended) An isolated nucleic acid comprising a nucleic acid sequence that is at least 90% identical to the sequence of the nucleic acid sequence of claim 41 and encodes a polypeptide that is capable of regulating steroid progesterone biosynthesis.

44. (Currently Amended) An isolated nucleic acid comprising a nucleic acid sequence that is at least 90% identical to the sequence of the nucleic acid sequence of claim 41 and encodes a polypeptide that is ~~capable of mediating~~ impairs cholesterol delivery.

45. (Cancel)

46. (Currently Amended) An isolated nucleic acid that encodes a polypeptide that is capable of regulating steroid progesterone biosynthesis and hybridizes to the complement of the nucleic acid of claim 41(a) or 41(b) under the following stringent conditions: a final wash in 0.1X SSC at 65°C.

U.S. Patent Appl. No. 09/762594
Attorney Docket No.: 076934-0277848

47. (Currently Amended) An isolated nucleic acid that encodes a polypeptide that is ~~capable of mediating~~ impairs cholesterol delivery and hybridizes to the complement of the nucleic acid of claim 41(a) or 41(b) under the following stringent conditions: a final wash in 0.1X SSC at 65°C.

48. (Allowed) A process of producing a peripheral-type benzodiazepine-associated protein (PAP) comprising culturing the host cell of either claim 15 or 16 under suitable conditions to express a peripheral-type benzodiazepine-associated protein-7 (PAP7) encoded by the nucleic acid.

49. (Allowed) The process of claim 48, wherein the vector further comprises a heterologous promoter operatively linked to the nucleotide sequence encoding the peripheral-type benzodiazepine-associated protein-7 (PAP7) polypeptide.

50. (Currently Amended) A ~~diagnostic~~ reagent comprising a nucleic acid of claim 41, wherein the nucleic acid is detectably labeled.

51. (Currently Amended) A ~~diagnostic~~ reagent comprising a single-stranded nucleic acid of claim 41, wherein the nucleic acid is complementary and is ~~detectable~~ detectably labeled.

52. (Currently Amended) A ~~diagnostic~~ reagent comprising a single-stranded nucleic acid of claim 41, wherein the nucleic acid amplifies peripheral-type benzodiazepine-receptor-associated protein-7 (PAP7) sequences.

53-56. (Cancel)

U.S. Patent Appl. No. 09/762594
Attorney Docket No.: 076934-0277848

57. (Previously Presented) A vector comprising the nucleic acid of claim 43.

58. (Previously Presented) A host cell comprising the vector of claim 57.

59. (Previously Presented) A process of producing a peripheral-type benzodiazepine-receptor-associated protein (PAP) comprising culturing the host cell of claim 58 under suitable conditions to express a peripheral-type benzodiazepine-receptor-associated protein-7 (PAP7) encoded by the nucleic acid.

60. (Currently Amended) A ~~diagnostic~~ reagent comprising a nucleic acid of claim 43, wherein the nucleic acid is detectably labeled.

61. (Previously Presented) A vector comprising the nucleic acid of claim 44.

62. (Previously Presented) A host cell comprising the vector of claim 61.

63. (Previously Presented) A process of producing a peripheral-type benzodiazepine-receptor-associated protein (PAP) comprising culturing the host cell of claim 62 under suitable conditions to express a peripheral-type benzodiazepine-receptor-associated protein-7 (PAP7) encoded by the nucleic acid.

64. (Currently Amended) A ~~diagnostic~~ reagent comprising a nucleic acid of claim 44, wherein the nucleic acid is detectably labeled.

U.S. Patent Appl. No. 09/762594
Attorney Docket No.: 076934-0277848

65-68. (Cancel)

69. (Previously Presented) A vector comprising the nucleic acid of claim 46.

70. (Previously Presented) A host cell comprising the vector of claim 69.

71. (Previously Presented) A process of producing a peripheral-type benzodiazepine-receptor-associated protein (PAP) comprising culturing the host cell of claim 70 under suitable conditions to express a peripheral-type benzodiazepine-receptor-associated protein-7 (PAP7) encoded by the nucleic acid.

72. (Currently Amended) A ~~diagnostic~~ reagent comprising a nucleic acid of claim 46, wherein the nucleic acid is detectably labeled.

73. (Previously Presented) A vector comprising the nucleic acid of claim 47.

74. (Previously Presented) A host cell comprising the vector of claim 73.

75. (Previously Presented) A process of producing a peripheral-type benzodiazepine-receptor-associated protein (PAP) comprising culturing the host cell of claim 74 under suitable conditions to express a peripheral-type benzodiazepine-receptor-associated protein-7 (PAP7) encoded by the nucleic acid.

U.S. Patent Appl. No. 09/762594
Attorney Docket No.: 076934-0277848

76. (Currently Amended) A ~~diagnostic~~ reagent comprising a nucleic acid of claim 47,
wherein the nucleic acid is detectably labeled.